# Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

> **NCT04511637** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 80 (actual)

## Conditions studied

- Clinical Pharmacology

## Interventions

- **DRUG:** Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
- **DRUG:** Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

## Key facts

- **NCT ID:** NCT04511637
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2019-03-07
- **Final completion:** 2019-04-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511637, "Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04511637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*